securities fraud

BlackRock TCP Capital faces class action lawsuit alleging false valuations and misleading net asset value disclosures. Shareholders who bought shares between November 2024 and January 2026 may participate.

CIBC and RBC face class action lawsuit for allegedly using spoofed orders to manipulate Quantum Biopharma stock price downward, harming investors from 2021-2025.

Class action lawsuit filed against Picard Medical for alleged fraud involving false social media statements and insider stock sales during inflated prices.

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.

Masonite faces class action lawsuit alleging executives concealed acquisition offers while repurchasing stock at depressed prices. Investors who bought shares June 2023-February 2024 are eligible.

Class action lawsuit filed against CoreWeave for allegedly making false statements about operational capabilities and customer demand fulfillment. Investors who purchased stock during specified period may seek lead plaintiff status.

uniQure faces class action lawsuit alleging misleading FDA approval statements and understated BLA timeline risks. Investors who purchased securities between September-October 2025 may be eligible to participate.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

Portnoy Law Firm filed securities class action against Ultragenyx Pharmaceutical, alleging the company made false statements about investigational drug setrusumab and concealed material clinical trial risks.

Kyndryl faces securities class action after disclosing internal control weaknesses, CFO/General Counsel departures, and 55% stock decline. Lead plaintiff deadline is April 13, 2026.

Ultragenyx faces securities lawsuit after failing to disclose setrusumab trial failure, causing 42% stock drop. Investors claim company withheld material information before December announcement.

CoreWeave faces securities class action alleging material misrepresentations about capacity and concealed data center supplier risks. Lead plaintiff applications due March 13, 2026.

BellRing Brands faces securities lawsuit for failing to disclose material information about business challenges between November 2024 and August 2025, leading to significant stock declines.

Rosen Law Firm sues Picard Medical for alleged fraudulent stock promotion and concealment of adverse information. Investors must act before April 13, 2026 deadline to become lead plaintiff.

Varonis Systems faces class action lawsuit after stock plunged 48.67% on October 29 following missed revenue projections and weak customer conversions disclosure.

BellRing Brands faces securities lawsuit alleging false statements about financial performance and growth. Class action covers November 2024 through August 2025 for affected investors.

Paysafe shareholders can join class action lawsuit until April 7, 2026, alleging the company made false statements and failed to disclose material issues affecting investors.

Class action lawsuit filed against Klarna for allegedly making false statements about risks associated with loan losses in its September 2025 IPO.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

Kyndryl Holdings faces securities lawsuit alleging false financial statements and inadequate internal controls, with shareholders from August 2024-February 2026 eligible to join the class action.